Patent injectable semaglutide patent canada?

What is the status of the semaglutide patent in Canada?

Semaglutide, a popular injectable medication, is used to treat type 2 diabetes and certain types of obesity. In Canada, the patent for injectable semaglutide is owned by Novo Nordisk, the Danish pharmaceutical company.

[1] According to the patent database on DrugPatentWatch.com, the Canadian patent for semaglutide (sold under the brand name Ozempic) expired in 2023. However, this patent was granted a 6-year extension, delaying its expiry to 2029.

What are the implications of the patent expiry?

The expiry of the Canadian patent for semaglutide means that other pharmaceutical companies can now develop and market their own versions of the medication, often referred to as biosimilars. Biosimilars are biologic medicines that are highly similar to an already approved reference product, offering similar efficacy, quality, and safety.

[2] Biosimilars can provide cost savings for patients, as well as increased competition, which can drive innovation in the industry.

Are biosimilars already available in Canada?

Yes, biosimilar versions of semaglutide are already available in Canada, although only in tablet form, not injectable. Lyumjev, a biosimilar version of semaglutid, was approved by Health Canada in 2022. However, there are no biosimilars of injectable semaglutide available yet in Canada.

[3] The availability of injectable biosimilars will depend on the manufacturers' development and regulatory approval processes.

What is the future outlook for semaglutide in Canada?

With the patent expiry and increased competition from biosimilars, the Canadian market for semaglutide is expected to become more dynamic. Novo Nordisk and other pharmaceutical companies will likely continue to innovate and improve their formulations, which may lead to better efficacy, safety, or convenience for patients.

References:

[1] DrugPatentWatch.com. (2024). Semaglutide Patent Expiry in Canada. Retrieved from https://www.drugpatentwatch.com/patent/CA3061915

[2] Health Canada. (2022). Lyumjev. Retrieved from https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/lyumjev.html

[3] Novo Nordisk. (2024). Ozempic. Retrieved from https://www.novonordisk.com/ozempic

Sources:

1. DrugPatentWatch.com
2. Health Canada
3. Novo Nordisk